The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthcare Professionals Who Are Trying to Quit.

What Was Tested

This registered not phased trial tested Therapeutic nicotine (patch, non-peptide).

Healthcare professionals play a key role in the fight against smoking.

It had three arms (groups): Music intervention and NRT (experimental), NRT Group (active comparator) and Healthy volunteers (other).

Combines music sessions and TSN for 3 months.

TSN alone for 3 months.

30 healthy volunteers for ancillary study MUSICAT-BIO.

The registry classes the interventions as drug, other and procedure.

Who Took Part

80 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Age \>=18 years old. To be a free subject, without guardianship, curatorship or subordination. Written Informed consent signed by the subject after receiving clear and honest information about the study. Healthcare professionals include administrative and technical professionals working in the healthcare sector in the private, public or independent sectors. Smoking at least 6 cigarettes per day for at least 6 months.

The full record lists 7 inclusion and 14 exclusion criteria; among the exclusions: unstabilized depression; psychosis and/or cognitive impairment and/or mental retardation or chronic use of medication for these disorders,; addictive comorbidity such as alcoholism or abuse of substances other than tobacco,.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2026-03-01 with completion listed for 2029-03-01.

It ran at 1 site in France.

Its stated primary purpose is prevention.

What Was Measured

It also tracked 6 secondary outcomes, for example Compare the evolution of craving between the two groups at 1, 2 and 3 months after the target date for smoking cessation, Compare the evolution of anxiety between the two groups at 1, 2 and 3 months after the target date for smoking cessation, Compare the evolution of impulsivity between the two groups at 1, 2 and 3 months after the target date for smoking cessation and Compare the evolution of anxiety between the two groups at 1, 2, 3 months after the target date for smoking cessation.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Therapeutic nicotine (patch, non-peptide) in 80 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.